{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T03:45:45Z","timestamp":1792381545264,"version":"4.4.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-infectious scleritis is a potentially sight-threatening condition in which the sclera, the white outer layer of the eye, becomes inflamed. Whilst scleritis can be infective, the majority of cases are due to non-infectious causes, often occurring in association with an underlying systemic autoimmune or auto-inflammatory condition. Thorough systemic work-up is crucial to identify disease aetiology and exclude infection; however, a significant proportion of disease remains idiopathic with the underlying cause unknown. Non-infectious scleritis is normally managed with systemic corticosteroid and immunosuppression, yet there is no widely agreed consensus on the most appropriate therapy, and no national or international guidelines exist for treatment of non-infectious scleritis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Standard systematic review methodology will be used to identify, select and extract data from comparative studies of pharmacological interventions used to treat patients with non-infectious scleritis. Searches of bibliographic databases (Cochrane Library, MEDLINE, CINAHL and EMBASE) and clinical trial registers will be employed. No restrictions will be placed on language or date of publication. Non-English articles will be translated where necessary. The primary outcome of interest will be disease activity measured by reduction in scleritis grading according to standardised grading systems. Secondary outcomes will include change in best corrected visual acuity, reduction in concurrent dose of systemic corticosteroid, time to treatment failure, adverse events and health-related quality of life. Risk of bias assessment will be conducted appropriate to each study design. Study selection, data extraction and risk of bias assessment will be completed by two reviewers independently. Data will be presented in a table and a narrative synthesis will be undertaken. Meta-analysis will be performed where methodological and clinical homogeneity exists. Subgroup and sensitivity analysis will be undertaken if appropriate.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Many studies have investigated the effectiveness of pharmacological agents used in the management of non-infectious scleritis. A systematic review is needed to collate and analyse this evidence. Findings of this systematic review will help guide ophthalmologists managing patients with non-infectious scleritis and may form the basis for evidence-based recommendations for future clinical practice and encourage standardisation of treatment protocols.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Systematic review registration<\/jats:title>\n                <jats:p>PROSPERO CRD42019125198<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13643-020-01314-9","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T14:02:50Z","timestamp":1584021770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness of pharmacological agents for the treatment of non-infectious scleritis: a systematic review protocol"],"prefix":"10.1186","volume":"9","author":[{"given":"Sathana","family":"Ingaralingam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saaeha","family":"Rauz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip I.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"1046","key":"1314_CR1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/postgradmedj-2011-130282","volume":"88","author":"J Sims","year":"2012","unstructured":"Sims J. Scleritis: presentations, disease associations and management. Postgrad Med J. 2012;88(1046):713\u20138.","journal-title":"Postgrad Med J."},{"issue":"2","key":"1314_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/01.iio.0000155900.64809.b2","volume":"45","author":"T Albini","year":"2005","unstructured":"Albini T, Rao N, Smith R. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin. 2005;45(2):191\u2013204.","journal-title":"Int Ophthalmol Clin"},{"issue":"12","key":"1314_CR3","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1016\/S0161-6420(99)90543-2","volume":"106","author":"PJ McCluskey","year":"2003","unstructured":"McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 2003;106(12):2380\u20136.","journal-title":"Ophthalmology."},{"issue":"4","key":"1314_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1517\/14656566.2013.772982","volume":"14","author":"RM Beardsley","year":"2013","unstructured":"Beardsley RM, Suhler EB, Rosenbaum JT, Lin P. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother. 2013;14(4):411\u201324.","journal-title":"Expert Opin Pharmacother."},{"issue":"3","key":"1314_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1136\/bjo.60.3.163","volume":"60","author":"P Watson","year":"1976","unstructured":"Watson P, Hayreh S. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163\u201391.","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"1314_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.survophthal.2005.04.001","volume":"50","author":"N Okhravi","year":"2019","unstructured":"Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2019;50(4):351\u201363.","journal-title":"Surv Ophthalmol."},{"issue":"3","key":"1314_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ajo.2007.09.024","volume":"145","author":"P Lin","year":"2008","unstructured":"Lin P, Bhullar S, Tessler H, Goldstein D. Immunologic markers as potential predictors of systemic autoimmune disease in patients with idiopathic scleritis. Am J Ophthalmol. 2008;145(3):463\u2013471.e1.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1314_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/09273948.2015.1005240","volume":"24","author":"A Lavric","year":"2015","unstructured":"Lavric A, Gonzalez-Lopez J, Majumder P, et al. Posterior scleritis: analysis of epidemiology, clinical factors, and risk of recurrence in a cohort of 114 patients. Ocul Immunol Inflamm. 2015;24(1):6\u201315.","journal-title":"Ocul Immunol Inflamm."},{"issue":"4","key":"1314_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0161-6420(91)32269-3","volume":"98","author":"S Tuft","year":"1991","unstructured":"Tuft S, Watson P. Progression of scleral disease. Ophthalmology. 1991;98(4):467\u201371.","journal-title":"Ophthalmology."},{"issue":"5","key":"1314_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10067-009-1368-8","volume":"29","author":"J Restrepo","year":"2010","unstructured":"Restrepo J, Molina M. Successful treatment of severe nodular scleritis with adalimumab. Clin Rheumatol. 2010;29(5):559\u201361.","journal-title":"Clin Rheumatol."},{"issue":"4","key":"1314_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ncprheum0454","volume":"3","author":"J Smith","year":"2007","unstructured":"Smith J, Mackensen F, Rosenbaum J. Therapy insight: scleritis and its relationship to systemic autoimmune disease. Nat Clin Pract Rheumatol. 2007;3(4):219\u201326.","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"1314_CR12","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/eye.1988.52","volume":"2","author":"C Calthorpe","year":"1988","unstructured":"Calthorpe C, Watson P, McCartney A. Posterior scleritis: a clinical and histological survey. Eye. 1988;2(3):267\u201377.","journal-title":"Eye."},{"issue":"8","key":"1314_CR13","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1001\/archopht.1979.01020020144012","volume":"97","author":"W Benson","year":"1979","unstructured":"Benson W, Shields J, Tasman W, Crandall A. Posterior scleritis a cause of diagnostic confusion. Arch Ophthalmol. 1979;97(8):1482\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"1314_CR14","first-page":"1215","volume":"8","author":"M Al Barqi","year":"2015","unstructured":"Al Barqi M, Behrens A, Alfawaz AM. Clinical features and visual outcomes of scleritis patients presented to tertiary care eye centers in Saudi Arabia. Int J Ophthalmol. 2015;8(6):1215\u20139.","journal-title":"Int J Ophthalmol."},{"key":"1314_CR15","doi-asserted-by":"publisher","unstructured":"Kempen JH, Pistilli M, Begum H, Fitzgerald TD, Liesegang TL, Payal A, Zebardast N, Bhatt NP, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Sen HN, Suhler EB, Thorne JE. Remission of non-infectious anterior scleritis: incidence and predictive factors. Am J Ophthalmol. 2019 Apr 2. pii: S0002-9394(19)30134-5. doi: https:\/\/doi.org\/10.1016\/j.ajo.2019.03.024. [Epub ahead of print].","DOI":"10.1016\/j.ajo.2019.03.024"},{"issue":"1","key":"1314_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/09273948.2015.1032308","volume":"24","author":"R Agrawal","year":"2016","unstructured":"Agrawal R, Lee CS, Gonzalez-Lopez JJ, Khan S, Rodrigues V, Pavesio C. Flurbiprofen: a nonselective cyclooxygenase (COX) inhibitor for treatment of noninfectious, non-necrotizing anterior Scleritis. Ocul Immunol Inflamm. 2016;24(1):35\u201342.","journal-title":"Ocul Immunol Inflamm."},{"issue":"1","key":"1314_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ophtha.2011.07.013","volume":"119","author":"M Sainz de la Maza","year":"2012","unstructured":"Sainz de la Maza M, Molina N, Gonzalez-Gonzalez L, Doctor P, Tauber J, Foster C. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43\u201350.","journal-title":"Ophthalmology."},{"issue":"5","key":"1314_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0002-9394(01)00830-3","volume":"131","author":"D Jabs","year":"2001","unstructured":"Jabs D, Rosenbaum J. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2001;131(5):679.","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"1314_CR19","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.survophthal.2016.06.002","volume":"61","author":"J Daniel Diaz","year":"2016","unstructured":"Daniel Diaz J, Sobol E, Gritz D. Treatment and management of scleral disorders. Surv Ophthalmol. 2016;61(6):702\u201317.","journal-title":"Surv Ophthalmol."},{"issue":"5-6","key":"1314_CR20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/08820538.2014.959203","volume":"29","author":"E Uchiyama","year":"2014","unstructured":"Uchiyama E, Papaliodis G, Lobo A, Sobrin L. Side-effects of anti-inflammatory therapy in uveitis. Semin Ophthalmol. 2014;29(5-6):456\u201367.","journal-title":"Semin Ophthalmol."},{"issue":"6","key":"1314_CR21","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S0031-3955(03)00121-4","volume":"50","author":"J Smith","year":"2003","unstructured":"Smith J, Nemeth T, McDonald R. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin North Am. 2003;50(6):1283\u2013300.","journal-title":"Pediatr Clin North Am."},{"key":"1314_CR22","unstructured":"Ingaralingam S, Murray P, Barry R. A systematic review of the effectiveness of pharmacological agents in the management of non-infectious scleritis. PROSPERO 2019. CRD42019125198 Available from: http:\/\/www.crd.york.ac.uk\/PROSPERO\/display_record.php?ID=CRD42019125198. Accessed 20 June 2019."},{"issue":"jul21 1","key":"1314_CR23","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(jul21 1):b2535.","journal-title":"BMJ"},{"key":"1314_CR24","doi-asserted-by":"crossref","unstructured":"Higgins JP, Green S. Cochrane handbook for systematic reviews of interventions: Cochrane book series: Wiley Blackwell:Chichester, England,Hoboken,NJ; 2008.","DOI":"10.1002\/9780470712184"},{"key":"1314_CR25","unstructured":"Wells G, Shea B, O\u2019connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses 2000 Available from: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (Accessed 27\/06\/2019)."},{"issue":"11","key":"1314_CR26","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21(11):1539\u201358.","journal-title":"Statistics in medicine."},{"issue":"10","key":"1314_CR27","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","volume":"61","author":"JL Peters","year":"2008","unstructured":"Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008;61(10):991\u20136.","journal-title":"J Clin Epidemiol"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-020-01314-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-020-01314-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:06:23Z","timestamp":1615507583000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-020-01314-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1186\/s13643-020-01314-9","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"14 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}